CD8A and neoplasm: Notably, the population of cDC1 (cluster MD_10), which has been reported to prime both CD4+ and CD8+ T cells and directly enhance the T cell-mediated anti-tumor immunity24, was enriched by V-Navo@gel treatment compared with PBS group and single Virus@gel treatment (Fig. 5g).